Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, Padova, Italy.
Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Hepatology. 2023 Oct 1;78(4):1149-1158. doi: 10.1097/HEP.0000000000000460. Epub 2023 May 17.
Removal/suppression of the primary etiological factor reduces the risk of decompensation and mortality in compensated cirrhosis. However, in decompensated cirrhosis, the impact of etiologic treatment is less predictable. We aimed to evaluate the impact of etiological treatment in patients with cirrhosis who developed ascites as single index decompensating event.
Patients with cirrhosis and ascites as single first decompensation event were included and followed until death, liver transplantation, or Q3/2021. The etiology was considered "cured" (alcohol abstinence, hepatitis C cure, and hepatitis B suppression) versus "controlled" (partial removal of etiologic factors) versus "uncontrolled." A total of 622 patients were included in the study. Etiology was "cured" in 146 patients (24%), "controlled" in 170 (27%), and "uncontrolled" in 306 (49%). During follow-up, 350 patients (56%) developed further decompensation. In multivariable analysis (adjusted for age, sex, varices, etiology, Child-Pugh class, creatinine, sodium, and era of decompensation), etiological cure was independently associated with a lower risk of further decompensation (HR: 0.46; p = 0.001). During follow-up, 250 patients (40.2%) died, while 104 (16.7%) underwent LT. In multivariable analysis, etiological cure was independently associated with a lower mortality risk (HR: 0.35, p < 0.001).
In patients with cirrhosis and ascites as single first decompensating event, the cure of liver disease etiology represents a main treatment goal since this translates into considerably lower risks of further decompensation and mortality.
在代偿期肝硬化中,去除/抑制原发性病因可降低失代偿和死亡风险。然而,在失代偿期肝硬化中,病因治疗的影响较难预测。我们旨在评估病因治疗对发生腹水这一单一失代偿事件的肝硬化患者的影响。
纳入了以腹水为首次单一失代偿事件的肝硬化患者,并对其进行随访,直至死亡、肝移植或 2021 年 9 月。病因被认为是“治愈”(戒酒、丙型肝炎治愈和乙型肝炎抑制)、“控制”(部分去除病因)还是“未控制”。共纳入 622 例患者。146 例(24%)患者的病因被“治愈”,170 例(27%)患者的病因被“控制”,306 例(49%)患者的病因未被“控制”。在随访期间,350 例患者(56%)发生进一步的失代偿。多变量分析(调整年龄、性别、静脉曲张、病因、Child-Pugh 分级、肌酐、钠和失代偿时代)表明,病因治愈与进一步失代偿的风险降低独立相关(HR:0.46;p = 0.001)。在随访期间,250 例患者(40.2%)死亡,104 例患者(16.7%)接受了肝移植。多变量分析表明,病因治愈与死亡率降低独立相关(HR:0.35,p < 0.001)。
在以腹水为首次单一失代偿事件的肝硬化患者中,治愈肝脏疾病病因是主要的治疗目标,因为这可显著降低进一步失代偿和死亡的风险。